Paricalcitol supplementation during the first year after kidney transplantation does not affect calcification propensity score

Area of Science:

• Nephrology
• Cardiology
• Pharmacology

Background:

• Cardiovascular complications are prevalent in kidney transplant recipients.
• Blood calcification propensity, measured by T50, is linked to cardiovascular outcomes.
• Paricalcitol influences calcium and phosphate metabolism, potentially affecting calcification.

Purpose of the Study:

• To evaluate the effect of paricalcitol supplementation on blood calcification propensity (T50) in kidney transplant recipients.
• To assess changes in T50 over one year in patients receiving paricalcitol versus no treatment.

Main Methods:

• A randomized study design was employed, comparing paricalcitol to a placebo group.
• Serum samples from 76 kidney transplant recipients were analyzed at 8 weeks and 1 year post-transplantation.
• T50 was measured to assess blood calcification propensity.

Main Results:

• No statistically significant differences in T50 were observed between the paricalcitol and placebo groups at baseline or at one year.
• T50 levels did not change significantly over time within either group or when data were pooled.
• Plasma PTH and baseline T50 were the only significant predictors of T50 after one year in multivariate analysis.

Conclusions:

• Paricalcitol treatment did not alter blood calcification propensity (T50) in kidney transplant recipients during the first year post-transplantation.
• T50 remained stable over the one-year study period in both treatment groups.
• These findings indicate that paricalcitol does not significantly impact this measure of calcification propensity in this patient cohort.